PURPOSE: The αvβ3 integrin is expressed in angiogenic vessels and is a potential target for molecular imaging of evolving pathological processes. Its expression is upregulated in cancer lesions and metastases as well as in acute myocardial infarction (MI) as part of the infarct healing process. The purpose of our study was to determine the feasibility of a new imaging approach with a novel (68)Ga-2,2',2″-(1,4,7-triazonane-1,4,7-triyl)triacetic acid (NOTA)-arginine-glycine-aspartic acid (RGD) construct to assess integrin expression in the evolving MI. METHODS: A straightforward labelling chemistry to attach the radionuclide (68)Ga to a NOTA-based chelating agent conjugated with a cyclic RGD peptidomimetic is described. Affinity for αvβ₃ integrin was assessed by in vitro receptor binding assay. The proof-of-concept in vivo studies combined the (68)Ga-NOTA-RGD with the flow tracer (13)N-NH₃ imaging in order to obtain positron emission tomography (PET)/CT imaging of both integrin expression and perfusion defect at 4 weeks after infarction. Hearts were then processed for immunostaining of integrin β₃. RESULTS: NOTA-RGD conjugate displayed a binding affinity for αvβ₃ integrin of 27.9 ± 6.8 nM. (68)Ga-NOTA-RGD showed stability without detectable degradation or formation of by-products in urine up to 2 h following injection in the rat. MI hearts exhibited (68)Ga-NOTA-RGD uptake in correspondence to infarcted and border zone regions. The tracer signal drew a parallel with vascular remodelling due to ischaemia-induced angiogenesis as assessed by immunohistochemistry. CONCLUSION: As compared to similar imaging approaches using the (18)F-galacto-derivative, we documented for the first time with microPET/CT imaging the (68)Ga-NOTA-RGD derivative that appears eligible for PET imaging in animal models of vascular remodelling during evolving MI. The simple chemistry employed to synthesize the (68)Ga-based radiotracer may greatly facilitate its translation to a clinical setting.
PURPOSE: The αvβ3 integrin is expressed in angiogenic vessels and is a potential target for molecular imaging of evolving pathological processes. Its expression is upregulated in cancer lesions and metastases as well as in acute myocardial infarction (MI) as part of the infarct healing process. The purpose of our study was to determine the feasibility of a new imaging approach with a novel (68)Ga-2,2',2″-(1,4,7-triazonane-1,4,7-triyl)triacetic acid (NOTA)-arginine-glycine-aspartic acid (RGD) construct to assess integrin expression in the evolving MI. METHODS: A straightforward labelling chemistry to attach the radionuclide (68)Ga to a NOTA-based chelating agent conjugated with a cyclic RGD peptidomimetic is described. Affinity for αvβ₃ integrin was assessed by in vitro receptor binding assay. The proof-of-concept in vivo studies combined the (68)Ga-NOTA-RGD with the flow tracer (13)N-NH₃ imaging in order to obtain positron emission tomography (PET)/CT imaging of both integrin expression and perfusion defect at 4 weeks after infarction. Hearts were then processed for immunostaining of integrin β₃. RESULTS: NOTA-RGD conjugate displayed a binding affinity for αvβ₃ integrin of 27.9 ± 6.8 nM. (68)Ga-NOTA-RGD showed stability without detectable degradation or formation of by-products in urine up to 2 h following injection in the rat. MI hearts exhibited (68)Ga-NOTA-RGD uptake in correspondence to infarcted and border zone regions. The tracer signal drew a parallel with vascular remodelling due to ischaemia-induced angiogenesis as assessed by immunohistochemistry. CONCLUSION: As compared to similar imaging approaches using the (18)F-galacto-derivative, we documented for the first time with microPET/CT imaging the (68)Ga-NOTA-RGD derivative that appears eligible for PET imaging in animal models of vascular remodelling during evolving MI. The simple chemistry employed to synthesize the (68)Ga-based radiotracer may greatly facilitate its translation to a clinical setting.
Authors: Hossam M Sherif; Antti Saraste; Stephan G Nekolla; Eliane Weidl; Sybille Reder; Arne Tapfer; Martina Rudelius; Takahiro Higuchi; René M Botnar; Hans-Jürgen Wester; Markus Schwaiger Journal: J Nucl Med Date: 2012-02 Impact factor: 10.057
Authors: Wouter A P Breeman; Erik de Blois; Ho Sze Chan; Mark Konijnenberg; Dik J Kwekkeboom; Eric P Krenning Journal: Semin Nucl Med Date: 2011-07 Impact factor: 4.446
Authors: Miikka Tarkia; Antti Saraste; Tiina Saanijoki; Vesa Oikonen; Tommi Vähäsilta; Marjatta Strandberg; Christoffer Stark; Tuula Tolvanen; Mika Teräs; Timo Savunen; Mark A Green; Juhani Knuuti; Anne Roivainen Journal: Nucl Med Biol Date: 2012-01-20 Impact factor: 2.408
Authors: David F Meoli; Mehran M Sadeghi; Svetlana Krassilnikova; Brian N Bourke; Frank J Giordano; Donald P Dione; Haili Su; D Scott Edwards; Shuang Liu; Thomas D Harris; Joseph A Madri; Barry L Zaret; Albert J Sinusas Journal: J Clin Invest Date: 2004-06 Impact factor: 14.808
Authors: Max Kiugel; Ingrid Dijkgraaf; Ville Kytö; Semi Helin; Heidi Liljenbäck; Tiina Saanijoki; Cheng-Bin Yim; Vesa Oikonen; Pekka Saukko; Juhani Knuuti; Anne Roivainen; Antti Saraste Journal: Mol Imaging Biol Date: 2014-12 Impact factor: 3.488
Authors: Hakan Orbay; Yin Zhang; Hector F Valdovinos; Guoqing Song; Reinier Hernandez; Charles P Theuer; Timothy A Hacker; Robert J Nickles; Weibo Cai Journal: Am J Nucl Med Mol Imaging Date: 2013-12-15
Authors: Thomas Ebenhan; Janke Kleynhans; Jan Rijn Zeevaart; Jae Min Jeong; Mike Sathekge Journal: Eur J Nucl Med Mol Imaging Date: 2020-09-12 Impact factor: 9.236
Authors: Ji-Ae Park; Yong Jin Lee; Ji Woong Lee; Kyo Chul Lee; Gwang Il An; Kyeong Min Kim; Byung Il Kim; Tae-Jeong Kim; Jung Young Kim Journal: ACS Med Chem Lett Date: 2014-07-10 Impact factor: 4.345
Authors: Thomas Rasmussen; Bjarke Follin; Jens Kastrup; Malene Brandt-Larsen; Jacob Madsen; Thomas Emil Christensen; Karsten Pharao Hammelev; Philip Hasbak; Andreas Kjær Journal: Diagnostics (Basel) Date: 2016-06-17